Therefore, in vivo imaging of immune biomarkers has thus far been limited to tumor models with a binary PD-L1 status, with tumors categorized as either PD-L1 overexpressing or PD-L1 negative based on arbitrary intensity thresholds (5, 24). This evidence concerns the gene CD274 and neoplasm.